Brief: Neuren Says Phase 2 trial shows significant improvements in Phelan-McDermid syndrome
18/12/2023 11:27
Dec 18 (Reuters) - Neuren Pharmaceuticals Ltd NEU.AX :
* NEUREN PHASE 2 TRIAL SHOWS SIGNIFICANT IMPROVEMENTS IN
PHELAN-MCDERMID SYNDROME
* NEUREN PHARMACEUTICALS LTD: NNZ-2591 WAS SAFE AND WELL
TOLERATED
* NEUREN PHARMACEUTICALS LTD: TOP-LINE RESULTS FROM PITT
HOPKINS
SYNDROME TRIAL ARE EXPECTED IN Q2 2024
Source text for Eikon: ID:nPn6TV6ta
Further company coverage: NEU.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neuren Pharmaceuticals
See all newsAustralia's Neuren set for weekly gain on FDA nod, drug forecast upgrade
Australia's Neuren Pharmaceuticals gains on upbeat FY trofinetide earnings outlook
Australia's Neuren Pharma rises as US FDA grants orphan tag for NNZ-2591
Strong partner sales propel Neuren Pharmaceuticals to top of Australia benchmark
Brief: Neuren Pharmaceuticals Says DAYBU Recommended For Approval In European Union